Superior Prognosis of Neoadjuvant Immunochemotherapy over Neoadjuvant Chemoradiotherapy in Esophageal Squamous Cell Carcinoma Patients with pCR.
BACKGROUND Neoadjuvant chemoradiotherapy (NCRT) is the standard regimen for locally advanced esophageal squamous cell carcinoma (ESCC), while neoadjuvant immunochemotherapy (NICT) has emerged as a promising alternative. Achieving pathological complete response (pCR) after neoadjuvant therapy is associated with favorabl...